Drug Type TCR therapy |
Synonyms ENGI-002 specTR, ENGI 002, ENGI002 |
Target |
Mechanism MAGEA3 inhibitors(Melanoma-associated antigen 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Engimmune Therapeutics AGStartup |
Active Organization Engimmune Therapeutics AGStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | CH | Engimmune Therapeutics AGStartup | 01 Oct 2024 |